Clinical Trial Search

Phase 3 N=1,651 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

Primary: Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) — 26.3; 31.7 Percentage…

Novartis Pharmaceuticals Results Oct 2018 28.1% serious AE View details

Phase 3 N=335 Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Pulmonary Arterial Hypertension

Primary: Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT) — 16; 11; 25; 11 Items

Actelion Results Oct 2018 17.3% serious AE View details

N/A N=80 Transversus Abdominis Plane Block Versus Wound Infiltration for Postcesarean Analgesia

Postcesarean Analgesia

Primary: Cumulative Fentanyl Dose — 157.4; 153.3 mcg

Mansoura University Results Oct 2018 0.0% serious AE View details

Phase 2 N=23 Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Low and Int 1-risk Myelodysplastic Syndrome

Primary: Difference in Percentage of Patients Achieving Erythroid Response Within 12 Weeks, by Treatment Group (Full Analysis Set) — 41.7; 27.3 percentage of participants

Novartis Pharmaceuticals Results Oct 2018 17.4% serious AE View details

Phase 4 N=230 Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Atherosclerosis · Hypercholesterolemia

Primary: Change in Mean of Wall Volume of Internal Carotid Arteries — -3.52; -5.91 Other - mm^3 ( cubic millimeter )

National Heart, Lung, and Blood Institute (NHLBI) Results Oct 2018 15.7% serious AE View details

Phase 3 N=60 Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

Congenital Bleeding Disorder · Haemophilia A

Primary: Incidence Rate of Factor VIII Inhibitors (Above or Equal to 0.6 BU (Bethesda Units)/mL) for the Main Phase of the Trial — 43.1 Percentage of participants

Novo Nordisk A/S Results Oct 2018 60.0% serious AE View details

Phase 3 N=12 Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Primary: Part A: Pre-dose Concentration (Ctrough) of LUM and IVA — 8710; 12300; 94.0; 216 nanogram per milliliter (ng/mL)

Vertex Pharmaceuticals Incorporated Results Oct 2018 5.6% serious AE View details

Phase 2 N=204 Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) — 91.1; 96.1 percentage of participants

Gilead Sciences Results Oct 2018 2.9% serious AE View details

N/A N=90 A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components

Chikungunya Virus · Dengue Virus

Primary: The Proportion of Transfused INTERCEPT Platelet Components With a Post-treatment Platelet Dose ≥ 3.0×10^11 Platelets. — 256 Platelet Components

Cerus Corporation Results Oct 2018 21.1% serious AE View details

Phase 2 N=30 Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome

Dry Eye Syndrome

Primary: Tear Film Break-up Time (TBUT) — 5.2; 4.7; 6.1; 7.3 seconds

Laboratorios Sophia S.A de C.V. Results Oct 2018 0.0% serious AE View details

Phase 3 N=67 Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

Fabry Disease

Primary: Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide…

Amicus Therapeutics Results Oct 2018 11.8% serious AE View details

Phase 2 N=27 The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

TTR-mediated Amyloidosis

Primary: The Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation — 26; 7; 2 participants

Alnylam Pharmaceuticals Results Oct 2018 25.9% serious AE View details

Phase 2 N=92 Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

Food Allergy

Primary: Sustained Unresponsiveness to Egg Consumption at 2 Years. — 3; 10; 7 Participants — p=0.009

Hugh A Sampson, MD Results Oct 2018 1.1% serious AE View details

Phase 2 N=21 A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

Primary: Percent of Participants Who Achieved Improvement in Motor Milestones as Assessed by Section 2 of the HINE at the Last Visit — 25.0; 68.8 Percent of participants

Biogen Results Oct 2018 80.0% serious AE View details

N/A N=31 A Wearable "Balance Booster" - Stepping Closer to the Market

Distorted; Balance · Sensation Disorders · Peripheral Neuropathy

Primary: Functional Gait Assessment (FGA) — 17; 7 Participants

RxFunction Inc. Results Oct 2018 0.0% serious AE View details